Frontiers in Immunology (Jun 2019)

Ponatinib Protects Mice From Lethal Influenza Infection by Suppressing Cytokine Storm

  • Si Chen,
  • Si Chen,
  • Ge Liu,
  • Ge Liu,
  • Jungang Chen,
  • Ao Hu,
  • Ao Hu,
  • Li Zhang,
  • Li Zhang,
  • Wenyu Sun,
  • Wenyu Sun,
  • Wei Tang,
  • Chunlan Liu,
  • Haiwei Zhang,
  • Chang Ke,
  • Jianguo Wu,
  • Xulin Chen,
  • Xulin Chen

DOI
https://doi.org/10.3389/fimmu.2019.01393
Journal volume & issue
Vol. 10

Abstract

Read online

Excessive inflammation associated with the uncontrolled release of pro-inflammatory cytokines is the main cause of death from influenza virus infection. Previous studies have indicated that inhibition of interferon gamma-induced protein 10 (IP-10), interleukin-8 (IL-8), monocyte chemoattractant protein 1 (MCP-1), or their cognate receptors has beneficial effects. Here, by using monocytic U937 cells that capable of secreting the three important cytokines during influenza A virus infection, we measured the inhibitory activities on the production of three cytokines of six anti-inflammatory compounds reported in other models of inflammation. We found that ponatinib had a highly inhibitory effect on the production of all three cytokines. We tested ponatinib in a mouse influenza model to assess its therapeutic effects with different doses and administration times and found that the delayed administration of ponatinib was protective against lethal influenza A virus infection without reducing virus titers. Therefore, we suggest that ponatinib may serve as a new immunomodulator in the treatment of influenza.

Keywords